# US 2012/0251580 A1 · Methods of use for a natural thomsen-friedenreich disaccharide compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251580 A1
- Document ID: US20120251580A1
- Status: Published application
- Kind: A1
- Application number: 13/430,938
- Filed: 2012-03-27
- Published: 2012-10-04
- Earliest claimed: 2011-03-31
- Assignees: University of Maryland, Baltimore
- Inventors: Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gerardo Vasta; Gargi Bandyopadhyaya
- Web page: https://patentgrep.com/patent/US20120251580A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A Thomsen-Friedenreich disaccharide-containing glycopeptide purified from cod fish of approximately 100 kDa (designated TFD100) and methods of using the same in the suppression of cancer metastasis is disclosed.

## Claims

### Claim 1

A method of suppressing metastasis in a subject comprising administering an effective amount of a TFD-containing glycopeptide to a subject having cancer, thereby suppressing metastasis in a subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TFD-containing glycopeptide is TFD100.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is prostate cancer.

### Claim 4 (depends on 1)

The method of claim 1, wherein a pharmaceutical formulation comprising from about 5 mg/kg to about 50 mg/kg of the TFD-containing glycopeptide to body weight is administered to the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 6

A method of suppressing gal3-mediated T cell apoptosis in a subject comprising administering an effective amount of a TFD-containing glycopeptide to a subject in need thereof, thereby suppressing gal3-mediated T cell apoptosis in a subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein the TFD-containing glycopeptide is TFD100.

### Claim 8 (depends on 6)

The method of claim 6, wherein the T cells are CD8+ T cells.

### Claim 9 (depends on 8)

The method of claim 8, wherein the CD8+ T cells are antigen-activated CD8+ T cells.

### Claim 10 (depends on 6)

The method of claim 6, wherein a pharmaceutical formulation comprising from about 5 mg/kg to about 50 mg/kg of the TFD-containing glycopeptide to body weight is administered to the subject.

### Claim 11 (depends on 6)

The method of claim 6, wherein the subject is a human.

### Claim 12

A method of suppressing tumor-induced T cell apoptosis in a subject comprising administering an effective amount of a TFD-containing glycopeptide to a subject having cancer, thereby suppressing tumor-induced T cell apoptosis in a subject.

### Claim 13 (depends on 12)

The method of claim 12, wherein the TFD-containing glycopeptide is TFD100.

### Claim 14 (depends on 12)

The method of claim 12, wherein the T cells are CD8+ T cells.

### Claim 15 (depends on 14)

The method of claim 14, wherein the CD8+ T cells are antigen-activated CD8+ T cells.

### Claim 16 (depends on 12)

The method of claim 12, wherein cells of the tumor express gal3 on their surface.

### Claim 17 (depends on 12)

The method of claim 12, wherein cancer is prostate cancer.

### Claim 18 (depends on 12)

The method of claim 12, wherein a pharmaceutical formulation comprising from about 5 mg/kg to about 50 mg/kg of the TFD-containing glycopeptide to body weight is administered to the subject.

### Claim 19 (depends on 12)

The method of claim 12, wherein the subject is a human.
